• Several other therapeutic op tions for patients with non-se vere COVID-19 at highest risk o f hospitalization are available: see decision support t ool that displays benefits and harms o f nirmatrelvir-ritonavir, molnupiravir, and remdesivir.
• The GDG c onsidered in vitro data demonstrating that neutr alization of currently circulating variants of SARS-CoV-2 and their subvariants with so trovimab is diminished.
• There was consensus among the panel that the meaningful r eduction o f in vitro neutralization activity str ongly sugg ests absenc e of clinical effectiveness o f monoclonal an tibodies such as so trovimab.
• There was also c onsensus regarding the need f or clinical trial evidence in order to confirm clinical effectiveness o f new monoclonal antibodies that r eliably neutralize circulating strains in vitro.

Resources and other considerations Acceptability and feasibility The strong recommendation against the use o f sotrovimab is further supported b y the challenges with a vailability and feasibility, such as limited pr oduction, intravenous administration and requirement for expertise to offer such treatment while oral antiviral therapies are also available.